Latest news with #SCHOTTPharma
Business Wire
19-05-2025
- Business
- Business Wire
CTP builds 18,000 sqm Serbian facility for SCHOTT Pharma as it expands global manufacturing network
AMSTERDAM--(BUSINESS WIRE)--Regulatory News: CTP, Europe's largest listed developer, owner, and manager of industrial and logistics properties by gross lettable area (GLA), has developed a new 18,000 sqm build-to-suit production facility for SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, at CTPark Jagodina in Serbia. SCHOTT Pharma will produce high-quality glass ampoules for vaccines and other medications from the industrial property, which marks an expansion of the company's global manufacturing network that now spans 15 countries. 180 people will be employed at the facility, which complements SCHOTT Pharma's 10 existing ampoule manufacturing sites across the globe, helping to safely deliver billions of injections every year. The property also benefits from CTP's high-quality modern building standards and sustainability-focused design. CTPark Jagodina offers outstanding regional connectivity, located just off Serbia's A1 highway and within reach of major cities including Belgrade (135 km), Niš (100 km), and multiple EU markets via direct road links. With a population of 400,000 within a 50 km radius and proximity to 20,000 students in nearby Kragujevac, the Park also provides access to skilled labour. CTPark Jagodina features energy-efficient buildings with BREEAM Very Good certifications, rooftop solar technology, water reuse systems, and modern amenities designed to support biodiversity and employee wellbeing. The park spans 22.9 hectares with 33,000 sqm of space already built, with 88,000 sqm planned for new development. Petar Kolognat, Business Development Director for CTP Serbia, commented: 'This partnership with SCHOTT Pharma is another shining example of how we support leading businesses in high-tech sectors by providing them with the strategic locations and scalable facilities they need. We are with our clients at every stage of their logistics property journeys, from site selection to construction, to the day-to-day management of their facilities. This ensures we understand our clients' individual needs and can deliver the real estate solutions that enable their businesses and people to thrive. SCHOTT Pharma's presence at CTPark Jagodina strengthens not only the park but the region's wider industrial ecosystem. The Park also provides SCHOTT Pharma with the flexibility to grow into more space with ample land available for new development.' Denis Nikitin, Plant Manager at SCHOTT Pharma, said: "We are very pleased with the support given by CTP from the start of the analysis and location search for our new plant all the way to the handover of the building. CTP offered and secured the most suitable location, surrounded by skilled workers in one of the most important industrial regions in Serbia. Through a close exchange of expertise with our teams across Europe and improved equipment, we look forward to reliably supplying our customers with the highest quality products from this location." CTP is the leading developer of industrial and logistics properties in Serbia, managing a total gross leasable area (GLA) of 600,000 sqm with an additional 200,000 sqm to be delivered in 2025. Serbia has become an attractive manufacturing destination for multinationals nearshoring their production to Europe to be closer to where their customers are located as they look to derisk supply chains and meet new EU regulations encouraging more production on the continent. CTP's parks are strategically located in Serbia's largest cities, including Belgrade, Novi Sad, Kragujevac, Jagodina, and Niš. Examples include CTPark Belgrade North and CTPark Belgrade West that offer Grade A logistics facilities with excellent transportation links to major European cities. They are also conveniently located near Nikola Tesla International Airport providing easy access to Europe's markets. ENDS About CTP CTP is Europe's largest listed owner, developer, and manager of logistics and industrial real estate by gross lettable area, owning 13.4 million sqm of GLA across 10 countries as at 31 March 2025. CTP certifies all new buildings to BREEAM Very good or better and earned a negligible-risk ESG rating by Sustainalytics, underlining its commitment to being a sustainable business. For more information, visit CTP's corporate website:
Yahoo
11-05-2025
- Business
- Yahoo
Are Investors Undervaluing SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) By 37%?
Using the 2 Stage Free Cash Flow to Equity, SCHOTT Pharma KGaA fair value estimate is €40.64 SCHOTT Pharma KGaA is estimated to be 37% undervalued based on current share price of €25.45 Analyst price target for 1SXP is €28.36 which is 30% below our fair value estimate Today we'll do a simple run through of a valuation method used to estimate the attractiveness of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) as an investment opportunity by taking the expected future cash flows and discounting them to their present value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (€, Millions) €43.2m €53.8m €99.7m €90.0m €172.0m €212.5m €248.2m €278.3m €302.8m €322.4m Growth Rate Estimate Source Analyst x4 Analyst x4 Analyst x4 Analyst x1 Analyst x1 Est @ 23.55% Est @ 16.81% Est @ 12.10% Est @ 8.80% Est @ 6.48% Present Value (€, Millions) Discounted @ 5.2% €41.1 €48.6 €85.7 €73.6 €134 €157 €174 €186 €192 €195 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = €1.3b After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.1%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 5.2%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = €322m× (1 + 1.1%) ÷ (5.2%– 1.1%) = €8.0b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €8.0b÷ ( 1 + 5.2%)10= €4.8b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is €6.1b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of €25.5, the company appears quite good value at a 37% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at SCHOTT Pharma KGaA as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.2%, which is based on a levered beta of 0.941. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for SCHOTT Pharma KGaA Strength Debt is not viewed as a risk. Dividends are covered by earnings and cash flows. Weakness Earnings declined over the past year. Dividend is low compared to the top 25% of dividend payers in the Life Sciences market. Opportunity Annual revenue is forecast to grow faster than the German market. Trading below our estimate of fair value by more than 20%. Threat Annual earnings are forecast to grow slower than the German market. Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For SCHOTT Pharma KGaA, we've compiled three further factors you should assess: Financial Health: Does 1SXP have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk. Future Earnings: How does 1SXP's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every German stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
07-05-2025
- Business
- Entrepreneur
TPG to Acquire 35% Stake in SCHOTT Poonawalla from Serum Institute of India
The transaction is expected to close in the first half of 2025. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Global investment firm TPG has entered into a binding agreement to acquire a 35% stake in SCHOTT Poonawalla Pvt Ltd, a leading drug packaging joint venture between Germany's SCHOTT Pharma and Serum Institute of India (SII), part of the Cyrus Poonawalla Group. SCHOTT Pharma, which focuses on drug containment and delivery systems, announced the deal and confirmed it would retain its 50% stake in the JV. Serum Institute will continue to hold a minority interest after the transaction. The deal is being funded by TPG Growth and co-investor Novo Holdings. Financial terms were not disclosed. The transaction is expected to close in the first half of 2025, subject to regulatory approvals and customary conditions. SCHOTT Poonawalla manufactures critical packaging products such as vials, syringes, and cartridges—vital components in the injectable drug and vaccine ecosystem. The JV serves a growing pharmaceutical market driven by rising demand for biologics and vaccines. "Having TPG join the partnership alongside SCHOTT Pharma and Serum Institute of India represents a significant milestone," the companies said in a joint statement. TPG, which manages USD 246 billion in assets, considers healthcare a core investment theme. "We are excited to partner with SCHOTT Pharma and Serum Institute and build upon SCHOTT Poonawalla's market leadership," said Bhushan Bopardikar, Business Unit Partner at TPG Growth. Adar Poonawalla, CEO of Serum Institute, added, "Their experience in healthcare investing and global network make them a strong partner." Jefferies and AZB & Partners advised on the deal, with J. Sagar Associates handling legal aspects.
&w=3840&q=100)
Business Standard
06-05-2025
- Business
- Business Standard
TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake
SCHOTT Pharma, a global player in drug containment and delivery solutions, announced on Tuesday that global investment firm TPG has acquired a 35 per cent stake in its Indian joint venture, SCHOTT Poonawalla, from the Serum Institute of India (SII). The investment, made through TPG Growth — the firm's middle-market and growth equity platform — includes Novo Holdings as a co-investor. Post-transaction, SCHOTT Pharma will continue to hold 50 per cent of the joint venture, while SII will retain a minority stake. The infusion of capital and expertise from TPG is expected to drive the company's next phase of growth and strengthen its position in the global pharmaceutical supply chain. The transaction, subject to customary closing conditions, is expected to be completed in the first half of 2025. SCHOTT Poonawalla, a collaboration between SCHOTT Pharma and SII — the world's largest vaccine manufacturer and part of the Cyrus Poonawalla Group — manufactures advanced drug containment systems, including cartridges for auto-injector pens, prefillable syringes, vials, and ampoules. It also provides regulatory services to pharma and biotech clients, including CDMOs (contract development and manufacturing organisations). Commenting on the development, Bhushan Bopardikar, business unit partner at TPG Growth, said: 'SCHOTT Poonawalla has established itself as a market leader with a world-class manufacturing base in India. We are excited to partner with SCHOTT Pharma and SII to accelerate the company's growth and innovation.' Adar Poonawalla, CEO of SII, said that while the company is partially exiting the joint venture, it will continue its collaboration with SCHOTT Pharma. 'TPG brings healthcare investing experience and a global network, which makes them a strong partner as SCHOTT Poonawalla scales and explores new opportunities,' he said. SCHOTT Pharma's CEO Andreas Reisse said India remains a key strategic manufacturing base for the company. 'Welcoming TPG to this partnership strengthens our presence in the Indian market and enhances our global reach,' he added. Ashok Saxena, managing director of SCHOTT Poonawalla, added that the company is focused on next-generation drug delivery systems. 'We're confident that TPG's track record in healthcare in India will be invaluable.' Jefferies advised TPG on the deal, with AZB & Partners and J Sagar Associates serving as legal advisors.
Mint
06-05-2025
- Business
- Mint
TPG acquires 35% stake in Schott Pharma from Serum Institute
US private equity firm TPG has entered into a binding agreement to acquire a 35% stake in the SCHOTT Poonawalla joint venture from Serum Institute of India (SII), the firms announced on Tuesday. TPG Growth, TPG's middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in SCHOTT Poonawalla. The total investment from TPG and Novo Holdings amounts to $300 million, according to one person with knowledge of the development. The partnership with TPG will aid the joint venture to scale up, 'equipping the company with additional resources and strategic insight to support its long-term global ambitions,' the companies said in a statement, adding that the deal was likely to close in the first half of 2025. Serum Institute of India had entered into a joint venture with SCHOTT Pharma, a German pioneer in drug containment and delivery solutions, in 2021. 'Partnering with TPG marks an important step for us,' Adar Poonawalla, chief executive of Serum Institute of India, said in the statement. 'Their experience in healthcare investing and global network make them a strong partner as we scale and explore new opportunities. Our collaboration with SCHOTT Pharma will continue, ensuring supply chain resilience and advancing innovation in vaccine packaging and delivery,' he added. Ashok Saxena, managing director of SCHOTT Poonawalla, said the entity was seeing increasing demand from pharmaceutical customers for advanced drug delivery and discovery solutions as they expand operations and shift towards more innovation and complex drug sales. 'We are excited to welcome TPG onboard as an investor, and are confident that their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla,' he added. SCHOTT Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company's portfolio includes cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and contract development and manufacturing organizations. SCHOTT Pharma, which has more than 1,800 customers, generated revenue of €957 million in FY24. 'We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla's market leadership position as India's largest injectables-focused drug containment solutions company,' Bhushan Bopardikar, business unit partner at TPG Growth, said in the statement. 'SCHOTT Pharma's innovation capabilities and pure-play focus on injectables will be complemented by TPG's local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector,' added Andreas Reisse, CEO at SCHOTT Pharma. 'As we continue to expand our local production capacities and leading role in that, this step will further enhance our global footprint and deliver exceptional value to our customers.' First Published: 6 May 2025, 12:20 PM IST
